Inflammation-related molecular signatures involved in the anticancer activities of brigatinib as well as the prognosis of EML4-ALK lung adenocarcinoma patient-Reference-Cited by-同舟云学术

Inflammation-related molecular signatures involved in the anticancer activities of brigatinib as well as the prognosis of EML4-ALK lung adenocarcinoma patient

Published:2024-02-15 Issue:6 Volume:45 Page:1252-1263
ISSN:1671-4083
Container-title:Acta Pharmacologica Sinica
language:en
Short-container-title:Acta Pharmacol Sin

Author:

Ge Fu-jing,Dai Xiao-yang,Qiu Yao,Liu Xiang-ning,Zeng Chen-ming,Xu Xiao-yuan,Chen Yi-dan,Zhu Hong,He Qiao-jun,Gai Ren-hua,Ma Sheng-lin,Chen Xue-qin,Yang Bo

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41401-024-01230-x.pdf

Reference41 articles.

1. Qin Z, Sun HH, Yue MT, Pan XW, Chen L, Feng XH, et al. Phase separation of EML4-ALK in firing downstream signaling and promoting lung tumorigenesis. Cell Discov. 2021;7:33.

2. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27:4247–53.

3. Camidge DR, Dziadziuszko R, Peters S, Mok T, Noe J, Nowicka M, et al. Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study. J Thorac Oncol. 2019;14:1233–43.

4. Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet. 2017;390:29–39.

5. Lin JJ, Zhu VW, Schoenfeld AJ, Yeap BY, Saxena A, Ferris LA, et al. Brigatinib in patients with alectinib-refractory ALK-positive NSCLC. J Thorac Oncol. 2018;13:1530–8.